Advances in the Management of Pancreatic Adenocarcinoma

Restricted access

Outcomes in pancreatic cancer are improving. The beneficial effects being achieved with adjuvant and neoadjuvant therapies, and the recent application of molecular profiling, both germline and somatic, are collectively impacting survival. The NCCN Guidelines for Pancreatic Cancer urge clinicians to undertake “agnostic” germline testing for all persons with pancreatic cancer. Fit patients should also be considered for adjuvant therapy with modified FOLFIRINOX (leucovorin, 5-FU, irinotecan, oxaliplatin). Novel therapies that focus on DNA damage repair strategies are proving to be important, but notably several late-stage trials of several other approaches, reported in the last year, proved disappointing.

Disclosures: Dr. O’Reilly has disclosed that she has received consulting fees from Celgene Corporation, CytomX Therapeutics, Loxo Oncology, Merck & Co., Inc., Silenseed, Polaris, Ipsen, Rafael Therapeutics, Sobi, and Pharmaceuticals, and her spouse has received consulting fees from Agios, Inc., AstraZeneca Pharmaceuticals LP, Bayer HealthCare, BeiGene, Berry Genomics, Bristol-Myers Squibb Company, Celgene Corporation, Debio, Eisai Inc., Eli Lilly and Company, Exelixis Inc., Flatiron Health, Inc., Genoscience Pharma, Incyte Corporation, Ipsen, LAM Research, Merck & Co., Inc., MINA, QED, Redhill Biopharma Ltd., SillaJen, twoXAR Pharmaceuticals, and Yiviva.

Correspondence: Eileen M. O’Reilly, MD, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, New York NY 10065. Email: oreillye@mskcc.org
  • 1.

    Lowery MA, Wong W, Jordan EJ, Prospective evaluation of germline alterations in patients with exocrine pancreatic neoplasms. J Natl Cancer Inst 2018;110:10671074.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Hu ZI, Shia J, Stadler ZK, Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: challenges and recommendations. Clin Cancer Res 2018;24:13261336.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Golan T, Hammel P, Reni M, Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med 2019;381:317327.

  • 4.

    O’Reilly EM, Lee JW, Zalupski M, Randomized, multicenter, phase II trial of gemcitabine, cisplatin +/- veliparib in patients with pancreas adenocarcinoma and a known germline BRCA/PALB2 mutation [abstract]. Presented at the 2020 Gastrointestinal Cancers Symposium; January 23–25, 2020; San Francisco, California. Abstract 639.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5.

    Conroy T, Hammet P, Hebbar M, Unicancer GI PRODIGE 24/CCTG PA.6 trial: a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine in patients with resected pancreatic ductal adenocarcinomas [abstract]. J Clin Oncol 2018;36(Suppl):Abstract LBA4001.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6.

    Neoptolemoa JP, Palmer DH, Ghaneh P, Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 2017;389:10111024.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    Tempero MA, Reni M, Riess H, APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine for surgically resected pancreatic adenocarcinoma [abstract]. Presented at the 2019 ASCO Annual Meeting; May 31–June 4, 2019; Chicago; Illinois. Abstract 4000.

    • Search Google Scholar
    • Export Citation
  • 8.

    Conroy T, Desseigne F, Ychou M, FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:18171825.

  • 9.

    Von Hoff DD, Ervin T, Arena FP, Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:16911703.

  • 10.

    Kim S, Signorovitch JE, Yang H, Comparative effectiveness of nab-paclitaxel plus gemcitabine vs FOLFIRINOX in metastatic pancreatic cancer: a retrospective nationwide chart review in the United States. Adv Ther 2018;35:15641577.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Dahan L, Phelip JM, Le Malicot K, FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: a randomized phase II trial (PRODIGE 35-PANOPTIMOX) [published online June 1, 2018]. J Clin Oncol , doi: 10.1200/JCO.2018.36

    • Search Google Scholar
    • Export Citation
  • 12.

    Wang-Gillam A, Li CP, Bodoky G, Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomized, open-label, phase 3 trial. Lancet. 2016;387:545557.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Gill S, Ko YJ, Cripps C, PANCREOX: a randomized phase III study of fluorouracil/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy. J Clin Oncol 2016;34:39143920.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Tempero MA, Van Cutsem E, Sigal D, HALO 109-301: a randomized, double-blind, placebo-controlled, phase III study of pegvorhyaluronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine in patients with previously untreated hyaluronan-high metastatic pancreatic ductal adenocarcinoma [abstract]. Presented at the 2020 Gastrointestinal Cancers Symposium; January 23–25, 2020; San Francisco, California. Abstract 638.

    • Search Google Scholar
    • Export Citation
  • 15.

    Boston Biomedical. Boston Biomedical, Inc. announces update on phase 3 CANSTE111P study of napabucasin in patients with metastatic pancreatic cancer following interim analysis. Accessed March 20, 2020. Available at: https://www.bostonbiomedical.com/news-and-media/20190701_boston-biomedical-inc-announces-update-canstem111p-study-following-interim-analysis/

    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 421 421 421
PDF Downloads 116 116 116
EPUB Downloads 0 0 0